Findings seen across three PICUs in England, but analysis shows events are largely preventable
FRIDAY, Dec. 10, 2021 (HealthDay News) — Adverse drug events (ADEs) are common in English pediatric intensive care units (PICUs), but are largely preventable, according to a study published online Dec. 8 in the British Journal of Clinical Pharmacology.
Anwar A. Alghamdi, Ph.D., from the University of Manchester in the United Kingdom, and colleagues assessed the incidence, nature, preventability, and severity of ADEs across three PICUs in England in 2019.
Among 302 patients, the researchers identified 62 confirmed ADEs (definite/probable causality), with one in six patients experiencing one or more ADEs. The incidence of ADEs was estimated at 20.5 per 100 patients and 16.7 per 1,000 patient-days. An expert panel judged the majority of ADEs (58 percent) as preventable. The medications most commonly implicated in ADEs involved the central nervous system (22.6 percent), infections (20.9 percent), and cardiovascular system (19.4 percent). Patients staying in the PICU for seven or more days were more likely to experience an ADE (odds ratio, 6.29) versus patients with a stay of one to six days.
“ADEs are common in English PICUs and most of them may be preventable. There is a strong association between ADE occurrence and duration of PICU stay, which represents a target for remedial interventions,” the authors write. “Exploring contributory factors of preventable ADEs is now necessary to inform preventive policies.”
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy
Study IDs Neurobiological Roots of Sensory Over-Responsivity